Author: Leios Therapeutics

Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness

September 14, 2026
Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101

August 30, 2026

Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness